Tag: Biotech and Pharma

Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion.

Την υπογραφή συμφωνίας με τη Boehringer Ingelheim International GmbH για την εξαγορά των δύο αναλγητικών φαρμακευτικών προϊόντων Lonarid N® και Lonalgal® για την αγορά της Ελλάδας και της Κύπρου με τη δυνατότητα να τα αξιοποιήσει και διεθνώς ανακοίνωσε σήμερα η Lavipharm A.E.

Pfizer Inc.’s stock tumbled 4% premarket Friday, after the company said it would not move to a Phase 3 trial of a twice-daily formulation of a weight-loss drug after patients in an earlier study had a lot of side effects.

Nov 30 (Reuters) – AbbVie said on Thursday it will buy drugmaker ImmunoGen for $10.1 billion, adding a promising drug for ovarian cancer to its portfolio of oncology treatments.

FRANKFURT, Nov 28 (Reuters) – Novartis has dialled up its sales growth target to 5% per year until 2027, citing demand for innovative drugs after the spin off of its generics business.

Bayer shares plunged to their lowest level in more than a decade after the group abandoned a key late-stage trial of a blood-thinning drug that was seen as a prospective blockbuster, saying it did not work as hoped.

Shares of Eli Lilly & Co. rose 0.67% in premarket trading Friday after drug giant announced plans to spend $2.5 billion to build a new manufacturing facility in Germany.

LONDON/COPENHAGEN, Nov 10 (Reuters) – Obesity drug maker Novo Nordisk said on Friday it will spend $6 billion to boost production in Denmark, although its chief executive warned the industry was far from being able to produce enough weight-loss drugs to meet global demand.

BioNTech U.S.-listed shares jumped more than 3% in premarket trading. BioNTech stock has declined 36% this year. Pfizer (PFE), which reported disappointing earnings last week, was up 0.2% in early trading Monday.

Eli Lilly reported third-quarter revenue and adjusted earnings that topped expectations, lifted by $1.4 billion in sales from its blockbuster diabetes drug Mounjaro.

Moderna posted a loss for the third quarter as demand for its Covid shots declined.

Novo Nordisk reported a surge in earnings and revenue on Thursday as it continues to benefit from the popularity of its weight-loss drugs. However, the company is still struggling with raising the supply of the drugs to meet demand.

Pfizer missed third-quarter estimates as the drugmaker saw more declines for its Covid-19 products.

Oct 27 (Reuters) – Sanofi  shares tumbled more than 15% after the French drugmaker abandoned its 2025 profit target under a plan to list its consumer healthcare business, while boosting its development spending plans to shore up its core innovative drugs business.

Merck reported third-quarter revenue and adjusted earnings that topped expectations.

Swiss health care company Roche on Monday announced it would acquire Telavant Holdings in a $7.1 billion transaction.

TOKYO, Oct 19 (Reuters) – Drugmaker Merck will pay Daiichi Sankyo $5.5 billion to jointly develop three of its candidate cancer drugs, they said, in a deal that could be worth up to $22 billion to the Japanese firm depending on the success of the cell-targeting therapies.

Johnson & Johnson topped quarterly earnings and revenue estimates.

COPENHAGEN, Oct 16 (Reuters) – Novo Nordisk (NOVOb.CO) has agreed to buy ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, from KBP Biosciences for up to $1.3 billion, the Danish drugmaker said on Monday.

Pfizer slashed its full-year earnings and revenue guidance Friday as it sees demand for its Covid treatment and vaccine wane.